KAZIA THERAPEUTICS LTD - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of August 2026 for Kazia Therapeutics Limited, a foreign private issuer. The filing details an underwritten public offering of securities entered into on August 28, 2026, with an expected closing date of August 31, 2026.
Key Financial Metrics and Capital Structure
The filing does not provide historical revenue, profit, cash flow, or margin data. The primary financial activity reported is the capital raise:
- Gross Proceeds: Approximately $40 million from the initial offering.
- Potential Additional Proceeds: Up to approximately $40 million from the exercise of Series A Warrants and up to approximately $40 million from Series B Warrants.
- Offering Price: $15.50 per ADS and accompanying Warrants.
- Underwriting Discount: 7% of gross proceeds.
- Net Proceeds: $14.415 per ADS and accompanying Warrants paid to the Company.
- Debt and Liquidity: The filing does not disclose current debt levels or specific liquidity balances prior to the offering. Management anticipates the proceeds will extend the cash runway into 2029.
Material Changes and Offering Details
The material change is the execution of an underwriting agreement for the sale of:
- 2,276,800 American Depositary Shares (ADSs).
- Pre-funded warrants to purchase up to 303,200 ADSs.
- Series A Warrants to purchase up to 2,243,478 ADSs (Exercise price: $17.825).
- Series B Warrants to purchase up to 2,064,000 ADSs (Exercise price: $19.375).
Underwriters include Leerink Partners LLC and Guggenheim Securities, LLC, with BTIG, LLC and Needham & Company, LLC as lead managers.
Guidance, Outlook, and Risks
Use of Proceeds: Funds are designated for the clinical development of paxalisib, specifically the Phase 1b trial in advanced triple-negative breast cancer (TNBC), and planned expansions into HR+/HER2- breast cancer, colorectal cancer, and early-stage high-risk TNBC. Remaining funds will be used for working capital and general corporate purposes.
Warrant Expiration Conditions:
- Series A: Expires 30 days after the Company announces that at least 12 patients in the Phase 1b TNBC trial achieve a six-month median progression-free survival, or five years from issuance, whichever is earlier.
- Series B: Expires 30 days after the Company announces that at least 12 patients in the HR+/HER2- breast cancer evaluation achieve a six-month median progression-free survival, or five years from issuance, whichever is earlier.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding clinical trial outcomes, regulatory approvals, and market conditions. There is a 60-day lock-up period for executive officers and directors following the underwriting agreement date.
Investor Verification Checklist
- Verify the final closing date of the offering and the actual net proceeds received.
- Monitor the Phase 1b trial data for paxalisib in advanced TNBC to determine the expiration timeline for Series A Warrants.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific representations, warranties, and indemnification obligations.
- Confirm the status of the planned clinical evaluations for HR+/HER2- breast cancer to assess Series B Warrant conditions.
- Check subsequent filings for updates on the cash runway extension into 2029.